The European Commission has accepted Germany's response on the regulation amending pharmacy operating rules. The notification procedure is therefore complete and Germany can promulgate the regulation. For medicine shipping, however, this is not deregulation: responsibility for the quality and efficacy of dispatched medicines is to remain entirely with the dispatching pharmacy.
The regulation completes a major part of Germany's pharmacy reform
The package includes a negotiation mechanism for pharmacy remuneration from 2028, renewed scope for customary early-payment discounts, changes affecting compounded preparations and branch pharmacies, and arrangements for continuity of care for chronically ill patients.
These measures create options, but they do not automatically secure the economics of community pharmacy. Discounts do not replace sustainable remuneration, branch pharmacies still require people and viable processes, and new care tasks need reimbursement, qualifications and operational capacity.
Brussels accepts removal of direct obligations for logistics companies
The notified draft originally included specific duties for both dispatching pharmacies and logistics companies. Following the Commission's detailed opinion, Germany stated that the proposed Sections 9a and 10(4) of the Medicinal Products Trade Ordinance and corresponding provisions would be deleted.
On 18 August 2026, the Commission called that response satisfactory. Its decisive understanding is that responsibility for quality and efficacy remains entirely with the dispatching pharmacy, while requirements aimed directly at logistics companies are removed.
This creates a demanding split: the pharmacy owns the pharmaceutical responsibility, while parcel networks, hubs, intermediate storage and subcontractors control important operational steps. The pharmacy must govern these outsourced activities well enough to discharge its own responsibility.
GDP becomes the practical quality benchmark
Delivery to an end consumer is not legally identical in every respect to pharmaceutical wholesale distribution. Even so, Good Distribution Practice provides the logical operational benchmark for risk-based, documented and auditable transport.
GDP-aligned shipping requires more than an assumption of next-day delivery. It needs transport risk assessments, qualification of critical lanes, suitable packaging, defined temperature conditions, controlled deviations and evidence that service providers and subcontractors can reproduce the agreed quality.
Core controls for a governed pharmaceutical shipping process
- risk-based qualification of lanes, transit times and providers,
- assessment of seasonal temperature extremes and delivery windows,
- qualified packaging and, where necessary, cooling concepts,
- visibility of hubs, intermediate storage and subcontractors,
- contractual quality, information, audit and escalation rights,
- records of delay, damage and temperature excursions,
- deviation assessment linked to CAPA, complaints and recall decisions,
- periodic performance review using pharmaceutical quality indicators.
Impact on mail-order pharmacies: QMS and supplier governance become critical
A standard parcel contract is insufficient when the pharmacy must demonstrate that the transport chain is suitable. Quality agreements should define responsibilities, transit times, temperature conditions, reporting, data access, subcontractors, complaints, audits and escalation.
The pharmacy QMS needs to connect product sensitivity, packaging selection, dispatch release, weekends and holidays, failed delivery, returns and deviation assessment. The decisive point is not the existence of an SOP, but its application and the availability of reliable data.
Costs will rise for QMS, supplier qualification, contract management, analytics and documentation. Large operators can fund dedicated quality teams and audit programmes. Smaller pharmacies may need shared standards, cooperation or specialist pharmaceutical-logistics partners.
Shipping models compared: what controlled medicine delivery adds
This matrix compares operating models, not individual providers. What matters is which controls the dispatching pharmacy can demonstrate for its products, routes and service partners.
| Control area | Standard parcel service | Controlled medicine delivery | QMS evidence |
|---|---|---|---|
| Product and risk | The parcel is handled as a general shipment | Product properties, sensitivity and destination market govern the process | Risk assessment, dispatch release and assortment rules |
| Temperature and packaging | No product-specific qualification is assumed | Season, transit time, lane and packaging are assessed by risk | Qualification report, packaging specification and monitoring plan |
| Transit and delivery | Service level and tracking are central | Weekends, holidays, intermediate storage and failed delivery are controlled | Lane and delivery rules, escalation matrix and data review |
| Providers and subcontractors | The contract primarily defines transport performance | Quality agreement, transparency and auditable responsibilities | Partner qualification plus audit and information rights |
| Deviations and returns | Damage or delay is handled as a logistics case | Pharmaceutical assessment, quarantine, CAPA and recall where required | Deviation record, CAPA and release or destruction decision |
| Performance and improvement | Parcel success and transit time | Pharmaceutical quality indicators by lane and provider | KPI review, management review and requalification |
Explore the building blocks: pharmacy QMS, temperature control, partner qualification and GDP training.
Impact on logistics providers: quality expectations do not disappear
Removing direct statutory duties does not remove pharmaceutical expectations from logistics. They move into tenders, quality agreements, service levels, audits and evidence requirements.
Providers offering transparent lane data, controlled hubs, defined temperature performance, documented deviations and governed subcontracting can differentiate themselves from ordinary parcel services. Digitally documented, GDP-aligned performance becomes a commercial quality advantage.
The contractual balance still matters: pharmacies carry the pharmaceutical responsibility but need information and control rights from much larger logistics partners. Without appropriate agreements and data, a gap opens between legal accountability and operational influence.
Comparable standards for domestic and cross-border shipping
Medicine safety and fair competition require comparable practical enforcement, whether the product is shipped by a German pharmacy or a cross-border fulfilment centre. Equivalent responsibility must produce equivalent evidence, inspections and consequences when deviations occur.
Formal accountability alone is insufficient. Supervisors and market participants need verifiable criteria for route suitability, temperature and transit-time risk, and the data required after an incident.
Ten implementation checks for mail-order pharmacies
- Segment the portfolio by product, time and temperature risk.
- Identify critical routes, regions, seasons and delivery models.
- Qualify packaging and shipping conditions.
- Assess providers and significant subcontractors.
- Update quality agreements with data, audit and escalation rights.
- Define scenarios for weekends, heat, frost and failed delivery.
- Connect deviations, CAPA, complaints, returns and recall.
- Review pharmaceutical quality indicators regularly.
- Train staff and verify real SOP use.
- Check promulgation and the effective date of each provision.
tiger.PHARMA: turning accountability into controlled processes
tiger.PHARMA combines hands-on pharmacy and pharmaceutical-wholesale experience with GDP, QMS, service-provider qualification and process design. We help pharmacies, e-pharmacies and logistics providers translate regulatory responsibility into documented, viable and auditable operations.
Official sources
- European Commission: TRIS notification 2026/0010/DE and response of 18 August 2026
- German Federal Ministry of Health: regulation amending pharmacy operating rules
Editorial analysis current at 20 August 2026. The promulgated final text, individual commencement provisions and supervisory practice are decisive.